GCG and obesity disorder: Concurrently, the increasing use of glucagon-like-peptide-1 (GLP) receptor agonists, approved by the Food and Drug Administration for the treatment of type 2 diabetes and obesity, has prompted concerns regarding delayed gastric emptying [13].